Public disclosures

Daewoong Co., Ltd

Company insiders · 10% owner · AEON Biopharma, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-10.Following & alerts
Reported transaction lines
3
Buy lines
0
Sell lines
0

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-113

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Daewoong Co., Ltd

10% owner · AEON Biopharma, Inc.

AEON

AEON Biopharma, Inc.

Exercise or conversion
Filing details

SEC transaction code X

Pre-Funded Warrant (right to buy) · Derivative security · Indirect ownership · By Daewoong Pharmaceutical Co., Ltd. · Reported balance after transaction: 0 · On October 30, 2026 (the "Exercise Date"), DWP exercised in full, on a cashless basis pursuant to Section 10 of the Pre-Funded Warrant, Pre-Funded Warrants to purchase 11,236,631 shares of Class A Common Stock at an exercise price of $0.0001 per share. No cash was paid by DWP in connection with the exercise. · The Pre-Funded Warrants were exercisable at any time on or after January 21, 2026 and did not expire until exercised in full. Following the exercise described in footnotes (2) and (3), no Pre-Funded Warrants remain outstanding. · Daewoong Co., Ltd. ("DWC") owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. ("DWP"), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. · None.

2026-10-302026-11-10

11,236,631 shares/units

SEC 4
Daewoong Co., Ltd

10% owner · AEON Biopharma, Inc.

AEON

AEON Biopharma, Inc.

Other transaction
Filing details

SEC transaction code J

Class A Common Stock, $0.0001 par value per share · Indirect ownership · By Daewoong Pharmaceutical Co., Ltd. · Reported balance after transaction: 23184523 · Represents 3,822 shares of Class A Common Stock withheld by the Issuer in satisfaction of the aggregate exercise price of the Pre-Funded Warrants in accordance with the net exercise formula set forth in the Pre-Funded Warrant, based on the closing sale price of $0.294 per share on October 29, 2026, the trading day immediately preceding the Exercise Date. As a result of the cashless exercise, 11,232,809 shares of Class A Common Stock were issued to DWP. · Daewoong Co., Ltd. ("DWC") owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. ("DWP"), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. · None.

2026-10-302026-11-10

3,822 shares/units

SEC 4
Daewoong Co., Ltd

10% owner · AEON Biopharma, Inc.

AEON

AEON Biopharma, Inc.

Exercise or conversion
Filing details

SEC transaction code X

Class A Common Stock, $0.0001 par value per share · Indirect ownership · By Daewoong Pharmaceutical Co., Ltd. · Reported balance after transaction: 23188345 · On October 30, 2026 (the "Exercise Date"), DWP exercised in full, on a cashless basis pursuant to Section 10 of the Pre-Funded Warrant, Pre-Funded Warrants to purchase 11,236,631 shares of Class A Common Stock at an exercise price of $0.0001 per share. No cash was paid by DWP in connection with the exercise. · Daewoong Co., Ltd. ("DWC") owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. ("DWP"), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. · None.

2026-10-302026-11-10

11,236,631 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement